To the Editor: Representing the International Prandial Glucose Regulation Study Group, A. Ceriello et al raised concerns about the results of our study [1] . We demonstrated the following: (1) impaired endothelium-dependent vasodilation (EDV) in type 2 diabetic women; (2) improved EDV after 3 months of tighter glycaemic control; (3) no acute EDV impairment 3 h after a high-fat meal; and (4) no difference in the postprandial EDV between the diabetic and non-diabetic group despite the expected higher excursions of metabolic parameters in the diabetic group.
Ceriello et al hypothesise that lipid-lowering, anti-hypertensive and sulphonylurea-based therapy may have 'counter-balanced' the adverse effects of the postprandial state. All diabetic participants were undertaking endothelium-ameliorating treatment (including metformin and aspirin) at the time of enrolment, but still had abnormal endothelial function. Therefore, we cannot accept the suggestion of Ceriello et al that such therapies could restore endothelial dysfunction specifically in the postprandial state in these diabetic subjects.
Ceriello et al asked whether 'a statin may have been used during the study', because patients had the same LDL levels as the control group and because, 'surprisingly', the HDL level decreased after intervention. Patients enrolled in this study prior to the Heart Protection Study and the Collaborative Atorvastatin Diabetes Study; therefore, only three of the 19 participants were taking statins at the time.
None of the patients started taking statins or other nonglucose-based regulating drugs during the study. Diabetic patients typically have 'combined dyslipidaemia', with population-average LDL concentrations, high triglyceride concentrations and low HDL concentrations. HDL and triglyceride levels generally improve with tighter glycaemic control. In this respect, we are not sure why Ceriello et al assume that statins were used during the study.
We disagree with the statement made by Ceriello et al that our 'failure [to control the postprandial excursions effectively] supports [their] hypothesis that perfect control of postprandial hyperglycaemia is essential in protecting the endothelium'. Even prior to glucose regulatory interventions, we could not demonstrate acute endothelial dysfunction in the postprandial state. We expect that clinicians involved in the care of diabetic patients will agree that a mean decrease in HbA 1 c of 0.96% (p<0.01) and a postprandial plasma glucose reduction of 18% (p<0.05) after 3 months of intervention is a good outcome and not a 'treatment failure'. In reality, using the therapies available to the majority of type 2 diabetic patients, 'perfect control of postprandial hyperglycaemia' is a near-impossible task.
We agree with Ceriello et al that studies of postprandial EDV need careful evaluation; postprandial EDV can not be concluded on the basis of a reduction in flow-mediated dilation (FMD) alone. However, such conclusions are frequently published, as in a study by Ceriello et al [2] . Postprandial FMD decreases spuriously [3] as a result of postprandial vasodilation [4] , because FMD represents a percentage change of the initial arterial diameter and because the dilatory capability of a vessel is inversely correlated to its initial diameter. In circumstances such as these, the initial arterial diameter values and the changes in absolute diameter must be reported [5] to show whether FMD reductions are a result of endothelial dysfunction or whether they are an artefact of the methods used.
